今晚新澳门9点35分开奖结果,49图库资料大全,澳门一肖中100%期期准海南特区号,2025澳门天天开好彩大全53期

Deputy Director of the Shenzhen Institute of Translational Medicine, MD, Full-time Principal Investigator (PI), Master's Supervisor, and Postdoctoral Co-supervisor

Recognized as a Forbes 30 Under 30 in Healthcare for Asia, Gen 40 Under 40 in Biopharmaceuticals, Guangdong Outstanding Young Scholar, and National Leading Talent in Shenzhen. I have led national key R&D projects, two general projects of the National Natural Science Foundation of China (NSFC), the NSFC Youth Fund, the Guangdong Natural Science Outstanding Youth Fund, Shenzhen Science and Technology Innovation Committee's discipline layout projects, and the Shenzhen Outstanding Youth Science Fund. I have served as an online reviewer for the NSFC, Guangdong Natural Science Outstanding Youth Fund, and national funds from Iceland and other European countries, as well as a second review expert for key projects of the Guangdong Joint Fund and Guangdong-Hong Kong-Macau Team projects.

As the first or corresponding author, I have published over 50 SCI papers in journals such as Nature Methods, Genome Biology, Nature Communications (3), eLife, Theranostics (2), and Clinical and Translational Medicine (2). I hold 10 national invention patents. I serve on the editorial boards of SCI journals including Cell Communication and Signaling, Cellular & Molecular Biology Letters, Minerva Biotecnologica, and Oncologie, and as a guest associate editor for Frontiers in Oncology, as well as a special issue editor for Frontiers in Cell and Developmental Biology and Frontiers in Molecular Biosciences. I have also been invited to review manuscripts for high-impact journals such as Nature Reviews Genetics, Nature Methods, Advanced Science, ACS Nano, Biosensors and Bioelectronics, and JACS.

Education:

September 2005 - July 2012:Shantou University Medical College, Combined Bachelor's and Master's Program

September 2012 - July 2015:Anhui Medical University, PhD

Professional Experience:

December 2017 - Present:Shenzhen Institute of Translational Medicine, Shenzhen Second People's Hospital

Full-time Principal Investigator (PI), Associate Researcher

May 2020 - March 2021:Shenzhen Institute of Translational Medicine, Shenzhen Second People's Hospital

Director of the Academic Department

March 2021 - Present:Shenzhen Institute of Translational Medicine, Shenzhen Second People's Hospital

Vice-Dean

National Natural Science Foundation of China, General Project, 8197110106: Research on Targeted Intervention of Early Bladder Cancer Using Artificial Gene Circuits Responsive to Intracellular lncRNA Combinations, 2020-01 to 2023-12, 550,000 RMB, ongoing, Principal Investigator.

National Natural Science Foundation of China, General Project, 81773257: Experimental Study on Precision Treatment of Bladder Cancer Using Novel CRISPR/dCas9-mediated Intelligent Gene Circuits, 2018-01 to 2021-12, 660,000 RMB, ongoing, Principal Investigator.

National Natural Science Foundation of China, Youth Science Fund Project, 81402103: Molecular Mechanism Study of MALAT1 Promoting Bladder Cancer Progression through miR-125b Downregulation, 2015-01 to 2017-12, 230,000 RMB, completed, Principal Investigator.

Guangdong Provincial Department of Science and Technology, Outstanding Youth Natural Science Fund, 2018B030306023: Research on Miniaturized CRISPR-dCas9 System Targeting Bladder Cancer, 2018-05 to 2021-05, 1 million RMB, ongoing, Principal Investigator.

Shenzhen Science and Technology Innovation Committee, Basic Research Plan Discipline Layout Project, JCYJ20180507184642475: Research on Oncolytic Adenovirus for Treating Advanced Tumors, 2019-04 to 2022-03, 2 million RMB, ongoing, Principal Investigator.

Shenzhen Science and Technology Innovation Committee, Excellent Scientific and Technological Innovation Talent Training Project (Outstanding Youth Basic Research), RCYX20200714114701035: Research on Targeted Recognition and Intervention of Bladder Cancer Using Mini Artificial Gene Circuits, 2021-04 to 2024-04, 2 million RMB, ongoing, Principal Investigator.

1）Liu Y, Zhan Y, Chen Z, et al. Directing cellular information flow via CRISPR signal conductors. Nature Methods. 2016;13(11):938-944. doi:10.1038/nmeth.3994

2）Zhan H, Zhou Q, Gao Q, Li J, Huang W, Liu Y. Multiplexed promoterless gene expression with CRISPReader. Genome Biology. 2019;20(1):113. Published 2019 Jun 3. doi:10.1186/s13059-019-1712-5

3）Liu Y, Huang W, Cai Z. Synthesizing AND gate minigene circuits based on CRISPReader for identification of bladder cancer cells. Nature Communications.  2020 Oct 30;11(1):5486.

4）Liu Y, Han J, Chen Z, Wu H, Dong H, Nie G. Engineering cell signaling using tunable CRISPR-Cpf1-based transcription factors. Nature Communications. 2017;8(1):2095. Published 2017 Dec 13. doi:10.1038/s41467-017-02265-x

5）Liu Y, Zeng Y, Liu L, et al. Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells. Nature Communications. 2014;5:5393. Published 2014 Nov 6. doi:10.1038/ncomms6393

6）Liu Y, Li J, Chen Z, Huang W, Cai Z. Synthesizing artificial devices that redirect cellular information at will. Elife. 2018;7:e31936. Published 2018 Jan 10. doi:10.7554/eLife.31936

7）Huang X, Chen Z, Liu Y*. RNAi-mediated control of CRISPR functions. Theranostics. 2020;10(15):6661-6673. Published 2020 May 17. doi:10.7150/thno.44880

8）Zhan H, Li A, Cai Z, Huang W, Liu Y*. Improving transgene expression and CRISPR-Cas9 efficiency with molecular engineering-based molecules. Clin Transl Med. 2020 Oct;10(6):e194.

Current Postdoctoral Researcher:

Du Yiqun

PhD Graduates:

He Ziqi (Graduated)

Huang Xinbo (Graduated)

Master's Graduates:

Ma Mengdan

Su Ganglin

Wang Baoyuan

Hu Kun (Graduated)

Xiao Junwen (Graduated)